Poor Liver Function Tied to Worse Survival Among HCC Patients on ICIs
Patients with advanced hepatocellular carcinoma have worse outcomes on immune checkpoint inhibitor therapy if they have worse liver function, a meta-analysis suggests.
Patients with advanced hepatocellular carcinoma have worse outcomes on immune checkpoint inhibitor therapy if they have worse liver function, a meta-analysis suggests.
Combination treatment with camrelizumab and rivoceranib is more effective than sorafenib monotherapy in patients with previously untreated, unresectable hepatocellular carcinoma, phase 3 data suggest.
A regulatory decision is expected on May 16, 2024.
Aspartame may be carcinogenic, according to the World Health Organization’s International Agency for Research on Cancer.
Higher levels of certain sex hormones are associated with an increased risk of some gastrointestinal cancers, a meta-analysis suggests.
Adjuvant treatment with atezolizumab and bevacizumab prolongs recurrence-free survival, when compared with active surveillance, in patients with hepatocellular carcinoma, a phase 3 study suggests.
Diets that promote inflammation and hyperinsulinemia may increase the risk of hepatocellular carcinoma, a study suggests.
Many cancer patients may be treated with drugs that were granted accelerated approval but do not provide a clinical benefit, a study suggests.
SBRT prior to sorafenib improved outcomes, compared with sorafenib alone, in a phase 3 trial of patients with advanced hepatocellular carcinoma.
The addition of transarterial chemoembolization to adjuvant sorafenib improved outcomes for patients with hepatocellular carcinoma and portal vein tumor thrombosis in a phase 2 trial.